8-K: DarioHealth Corp. Completes Acquisition of Twill, Inc., Pro Forma Financials Released

DarioHealth Corp. has finalized its acquisition of Twill, Inc., and released pro forma financial statements reflecting the combined entity's performance.

Summary

• DarioHealth Corp. acquired Twill, Inc. on February 15, 2024, through a merger with a subsidiary.
• The acquisition involved a cash payment of $10 million and the issuance of pre-funded warrants for 10,000,400 shares of DarioHealth stock.
• Twill's audited financial statements for the year ended December 31, 2023, show a net loss of $30.7 million and revenues of $18.2 million.
• The pro forma combined financial statements for 2023 show a net loss of $87.5 million and revenues of $38.5 million.
• The pro forma balance sheet includes $54.3 million in goodwill and $24.8 million in intangible assets.
• The merger agreement also includes the appointment of a new board member nominated by Twill's equity holders.
• DarioHealth issued stock options for 2,963,459 shares to Twill employees and warrants and RSUs for 1,766,508 shares to Twill's outgoing board members and officers.

Sentiment

Score: 4

Explanation: The document highlights a significant acquisition but also reveals substantial losses and a going concern warning for Twill, leading to a negative sentiment overall.

Positives

• The acquisition expands DarioHealth's market presence and capabilities.
• The combined entity has a pro forma revenue of $38.5 million, indicating a larger scale of operations.
• The merger includes the addition of a new board member with expertise from Twill's side.

Negatives

• Twill had a significant net loss of $30.7 million in 2023.
• The pro forma combined entity shows a substantial net loss of $87.5 million for 2023.
• The acquisition resulted in a significant amount of goodwill, which may be subject to impairment in the future.
• Twill had a history of losses and a going concern warning.

Risks

• The combined entity faces the challenge of integrating Twill's operations and technology.
• The substantial net loss of the combined entity raises concerns about profitability.
• The high amount of goodwill could lead to future impairment charges.
• Twill's historical financial statements included a going concern warning, indicating potential financial instability.

Future Outlook

The pro forma financial information is for illustrative purposes only and does not project the future financial condition or results of operations of the combined company. The actual results may differ significantly.

Industry Context

The acquisition of Twill by DarioHealth reflects a trend of consolidation in the digital therapeutics industry, where companies are seeking to expand their product offerings and market reach through mergers and acquisitions.

Comparison to Industry Standards

• Twill's revenue of $18.2 million is relatively low compared to established digital health companies, such as Teladoc Health, which reported revenues in the billions.
• The net loss of $30.7 million for Twill is significant and indicates a lack of profitability, which is not uncommon for early-stage digital health companies.
• The pro forma combined net loss of $87.5 million is substantial and highlights the challenges of achieving profitability in the digital health sector.
• The goodwill of $54.3 million is a significant portion of the combined company's assets, which is typical in acquisitions where the purchase price exceeds the fair value of tangible assets.

Management Changes

Related Party Transactions

• Twill had loan transactions with related parties, including shareholders who provided term and convertible loans.

Stakeholder Impact

• Shareholders of DarioHealth will see a dilution of their ownership due to the issuance of new shares and warrants.
• Employees of Twill will become employees of DarioHealth, with new stock options.
• Customers of both companies will experience a combined product offering.
• Creditors of Twill were paid out as part of the acquisition.

Next Steps

• DarioHealth will integrate Twill's operations and technology.
• A new board member nominated by Twill's equity holders will be appointed within 90 days.
• The company will work to realize cost and growth synergies from the merger.

Key Dates

Keywords

acquisition, merger, pro forma, financial statements, digital therapeutics, healthcare, goodwill, intangible assets, net loss, revenue